The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Survival benefit from bevacizumab in newly diagnosed glioblastoma (GBM) according to transcriptional subclasses.
Jason T. Huse
No relevant relationships to disclose
Kathryn Beal
No relevant relationships to disclose
Jianan Zhang
No relevant relationships to disclose
Edward R. Kastenhuber
No relevant relationships to disclose
Thomas Joseph Kaley
No relevant relationships to disclose
Lauren E. Abrey
Employment or Leadership Position - Roche
Philip H. Gutin
Consultant or Advisory Role - Novocure; Pharmaco-Kinesis
Cameron W Brennan
No relevant relationships to disclose
Antonio Marcilio Padula Omuro
Consultant or Advisory Role - Novocure; Roche